Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Sung-Hoon | - |
dc.contributor.author | Lee, Je-Jung | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Min, Chang-Ki | - |
dc.contributor.author | Kim, Kihyun | - |
dc.contributor.author | Choi, Yunsuk | - |
dc.contributor.author | Eom, Hyeon-Seok | - |
dc.contributor.author | Joo, Young Don | - |
dc.contributor.author | Kim, Sung-Hyun | - |
dc.contributor.author | Kwak, Jae-Yong | - |
dc.contributor.author | Kang, Hye Jin | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Lee, Ho Sup | - |
dc.contributor.author | Mun, Yeung-Chul | - |
dc.contributor.author | Moon, Joon Ho | - |
dc.contributor.author | Sohn, Sang Kyun | - |
dc.contributor.author | Park, Seong Kyu | - |
dc.contributor.author | Park, Yong | - |
dc.contributor.author | Shin, Ho-Jin | - |
dc.contributor.author | Yoon, Sung-Soo | - |
dc.date.accessioned | 2021-09-02T11:43:40Z | - |
dc.date.available | 2021-09-02T11:43:40Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2018-05 | - |
dc.identifier.issn | 1083-8791 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/75605 | - |
dc.description.abstract | This prospective study evaluated the efficacy and toxicity of intravenous busulfan and melphalan as a conditioning regimen for autologous stern cell transplantation (ASCT) in patients with multiple myeloma (MM). A total of 99 patients with MM, enrolled between January 2013 and March 2016, received intravenous busulfan (9.6 mg/kg) and melphalan (140 mg/m(2)) before ASCT. The median time to transplant was 6.2 months, and 90 (90.9%) patients underwent ASCT within 12 months of the diagnosis. The overall response rate after ASCT was 94.0%, including 43.5% with a stringent complete response/complete response, 27.3% with very good partial response, and 23.2% with partial response. The most common severe nonhematologic toxicity (grade 3 to 4) was infection (26.3%) and stomatitis (15.2%). Three (3.2%) patients developed veno-occlusive disease. No treatment-related mortality was observed. After a median follow-up of 26.1 months, the median progression free survival was 27.2 months (range, 13.0 to 41.4 months) and median overall survival was not reached. In conclusion, a conditioning regimen of intravenous busulfan and melphalan was effective and tolerable. ClinicalTrials.gov. number: NCT01923935 (C) 2018 American Society for Blood and Marrow Transplantation. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.subject | HIGH-DOSE MELPHALAN | - |
dc.subject | BONE-MARROW-TRANSPLANTATION | - |
dc.subject | VENOOCCLUSIVE DISEASE | - |
dc.subject | COMPLETE RESPONSE | - |
dc.subject | SPANISH REGISTRY | - |
dc.subject | THERAPY | - |
dc.subject | TRIAL | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | BORTEZOMIB | - |
dc.subject | LIVER | - |
dc.title | Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150) | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Yong | - |
dc.identifier.doi | 10.1016/j.bbmt.2018.01.004 | - |
dc.identifier.scopusid | 2-s2.0-85041640651 | - |
dc.identifier.wosid | 000433400000007 | - |
dc.identifier.bibliographicCitation | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, v.24, no.5, pp.923 - 929 | - |
dc.relation.isPartOf | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | - |
dc.citation.title | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | - |
dc.citation.volume | 24 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 923 | - |
dc.citation.endPage | 929 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Transplantation | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Transplantation | - |
dc.subject.keywordPlus | HIGH-DOSE MELPHALAN | - |
dc.subject.keywordPlus | BONE-MARROW-TRANSPLANTATION | - |
dc.subject.keywordPlus | VENOOCCLUSIVE DISEASE | - |
dc.subject.keywordPlus | COMPLETE RESPONSE | - |
dc.subject.keywordPlus | SPANISH REGISTRY | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | BORTEZOMIB | - |
dc.subject.keywordPlus | LIVER | - |
dc.subject.keywordAuthor | Intravenous busulfan | - |
dc.subject.keywordAuthor | Melphalan | - |
dc.subject.keywordAuthor | Multiple myeloma | - |
dc.subject.keywordAuthor | Autologous transplantation | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.